New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export TVRD’s income statement to Excel — free account
Tvardi Therapeutics, Inc.
TVRDTvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.
- Revenue
- +20.3%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
0.99
0.04
+4.21%
After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.
Follow TVRD
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 0 | 1 | 13 | 20 | 135 | 23 | 42 | 21 | 7 | — | 8 | +73.7% | 42 | 47 | — | +13.2% | |
| Gross margin, % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 82.65 | 70.56 | 91.31 | — | 146.85 | (8.7) pt | ||||||
| EBT | (58) | (58) | (74) | (107) | 8 | (88) | (85) | (119) | (29) | (18) | (27) | n/m | ||||||
| EBT margin, % | (67,148.84) | (6,402.74) | (552.39) | (539.02) | 5.71 | (384.06) | (204.16) | (565.21) | (411.90) | — | (109.36) | +66,736.9 pt | ||||||
| Net income | (57) | (58) | (74) | (106) | 8 | (88) | (85) | (119) | (29) | (18) | (27) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.11 | 1.05 | 13.52 | 16.79 | 102.61 | 16.35 | 28.09 | 13.94 | 2.77 | — | 2.94 | +49.1% | |||||
| Earnings | (75.64) | (66.99) | (74.20) | (89.68) | 6.48 | (62.67) | (57.27) | (78.88) | (11.42) | (2.46) | (2.68) | n/m | ||||||
| Cash flow | (62.56) | (63.29) | (22.38) | (92.20) | (4.17) | (42.67) | (52.83) | (61.23) | (7.11) | (3.17) | (2.15) | n/m | ||||||
| Capex | (0.95) | (0.02) | (0.07) | (0.02) | (0.27) | 0.02 | (0.03) | (1.58) | (0.41) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (63.50) | (63.31) | (22.45) | (92.21) | (4.43) | (42.65) | (52.86) | (62.81) | (7.52) | (3.17) | (2.15) | n/m | ||||||
| Book value | 66.97 | 100.17 | 134.10 | 157.60 | 189.15 | 161.57 | 106.55 | 37.96 | (35.40) | 2.82 | 1.22 | (29.7%) | ||||||
| Shares, m | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 7 | 10 | +28.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | n/m | n/m | n/m | n/m | 168.02 | n/m | n/m | n/m | n/m | — | n/m | 168.0 | |||||
| P/S | 3,094.60 | 401.66 | 32.43 | 34.55 | 5.31 | 4.57 | 14.03 | 1.95 | 6.62 | — | 1.65 | 399.5 | ||||||
| P/B | 5.25 | 4.61 | 3.49 | 3.68 | 2.88 | 2.71 | 3.70 | 0.72 | 0.00 | — | 0.81 | 3.0 | ||||||
| EV/Sales | 2,408.83 | 308.81 | 21.18 | 26.93 | 4.00 | 3.35 | 10.55 | (2.87) | 6.43 | — | (1.29) | 309.7 | ||||||
| EV/FCF | (4.31) | (5.61) | (13.62) | (4.90) | (92.50) | (7.53) | (5.61) | 0.64 | (2.14) | — | 0.36 | (15.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (47) | (55) | (22) | (109) | (5) | (60) | (79) | (92) | (18) | (23) | (27) | n/m | |||||
| Capex | (1) | 0 | 0 | 0 | 0 | 0 | 0 | (2) | (1) | — | — | +4.8% | ||||||
| Free cash flow | (48) | (55) | (22) | (109) | (6) | (60) | (79) | (94) | (19) | (23) | (27) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 50 | 87 | 128 | 123 | 177 | 156 | 145 | 91 | 21 | 20 | 15 | (9.4%) | |||||
| Net debt | (59) | (93) | (162) | (152) | (177) | (165) | (146) | (101) | (1) | (31) | (22) | n/m | ||||||
| Shareholders’ equity | 51 | 87 | 134 | 187 | 249 | 228 | 159 | 57 | (91) | 21 | 15 | (9.4%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (65.57) | (72.28) | (51.43) | (50.20) | 3.34 | (34.13) | (39.82) | (76.94) | (36.51) | (54.15) | (85.24) | +11.4 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | (199.09) | 4.69 | (89.22) | (421.75) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (73.54) | (84.54) | (67.16) | (66.41) | 3.86 | (37.12) | (44.25) | (109.80) | 172.69 | 51.90 | (123.08) | +125.4 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 34 | 37 | 55 | 67 | 80 | 84 | 106 | 55 | 10 | 12 | — | (10.9%) | |||||
| Revenue/emp, $m | 0.00 | 0.02 | 0.24 | 0.30 | 1.69 | 0.27 | 0.39 | 0.38 | 0.71 | — | — | +102.4% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Mar 2025 · fundamentals updated Nov 17, 2026
Tvardi Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BOLT Bolt Biotherapeutics, Inc. | $13.2M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +68.66% (above 0%: growing) | 100.00% | (167,480.00%) | Compare |
| ACTU Actuate Therapeutics, Inc. | $12.9M | — (loss-making) | — | — | n/m | +55.81% (above 0%: growing) | — | — | Compare |
| GUTS Fractyl Health, Inc. | $12.7M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +30.87% (above 0%: growing) | 100.00% | (840,333.33%) | Compare |
| TVRD Tvardi Therapeutics, Inc. | $12.6M | — (loss-making) | — (loss-making) | +20.33% (above 0%: growing) | n/m | −49.89% (below 0%: shrinking) | 100.00% | (169.48%) | |
| QNTM Quantum Biopharma Ltd. | $12.6M | — (loss-making) | — (loss-making) | — | n/m | −197.94% (below 0%: shrinking) | 0.00% | (79,749.48%) | Compare |
| NEUP Neuphoria Therapeutics Inc. | $12.6M | — (loss-making) | — (loss-making) | — | n/m | +70.26% (above 0%: growing) | 100.00% | 43,872.18% | Compare |
| DYAI Dyadic International Inc. | $12.5M | — (loss-making) | — (loss-making) | −61.44% (below 0%: shrinking) | n/m | +19.88% (above 0%: growing) | 16.48% | (403.56%) | Compare |
| CASIF CASI Pharmaceuticals Inc. | $12.4M | — (loss-making) | — (loss-making) | −45.93% (below 0%: shrinking) | n/m | — | 51.14% | (147.67%) | Compare |
| JSPR Jasper Therapeutics, Inc. | $11.9M | — (loss-making) | — | — | n/m | +67.81% (above 0%: growing) | 0.09% | (1,802.16%) | Compare |
| Median of peers | $12.6M | — | — | −59.29% | — | +55.81% | 51.14% | (1,802.16%) |
Pay and ownership Proxy statement filed Apr 23, 2026
Ownership
Directors and executive officers, together
7.40%
Entities affiliated with Sporos
8.90%
Entities affiliated with Solas BioVentures
8.10%
Entities affiliated with Slate Path
7.50%
David J. Tweardy
7.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Tvardi Therapeutics, Inc. (TVRD) Latest News
What happened
- Other Tvardi Therapeutics received FDA pre-IND feedback supporting proposed Phase 2 development of TTI-109 in ulcerative colitis and potentially Crohn’s disease.
- Results Tvardi Therapeutics reported a third-quarter 2026 net loss of $6.1 million and said its $22.3 million in cash was expected to fund operations into Q3 2027.
- Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
- TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
- Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
- Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update GlobeNewswire
- Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights GlobeNewswire
- Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks
- Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update Business Wire
- Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now Zacks
- TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals Zacks
- Why Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial Results Simply Wall St.
18 more headlines
- New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC) GlobeNewswire
- Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
- Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update GlobeNewswire
- We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate Simply Wall St.
- Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswireInsider MonkeySimply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.
- Tvardi: Q3 Earnings Snapshot Associated Press Finance
- Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround ZacksMT NewswiresZacksSimply Wall St.ZacksZacksZacksZacks
- Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis Business WireClinical Trials ArenaZacksPharmaceutical TechnologySimply Wall St.Clinical Trials ArenaClinical Trials ArenaSimply Wall St.
- Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26% Simply Wall St.
- Tvardi Therapeutics (NASDAQ:TVRD) Is In A Good Position To Deliver On Growth Plans
- Tvardi: Q2 Earnings Snapshot
- Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update Business Wire
- This ‘Strong Buy’ Stock Could Be the Next Big Biotech Breakout Barchart
- Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks TipRanks
- Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis Business Wire
- Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
- Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
- Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics GlobeNewswire